SG Americas Securities’s Freeline Therapeutics Holdings FRLN Stock Holding History
Bought
Maintained
Sold
Other funds holding FRLN
SG Americas Securities's FRLN Position: Q3 2022 in Review
SG Americas Securities sold out of Freeline Therapeutics Holdings (FRLN) in Q3 2022, closing a stake of 3,444 shares — an estimated $45K sold.
SG Americas Securities first reported a position in FRLN in Q3 2021 and held it in 4 quarters. The position peaked at $163K in Q3 2021. 14 funds tracked by Wall St. Rank hold FRLN as of Q3 2022.
- SG Americas Securities reported no remaining Freeline Therapeutics Holdings position as of Q3 2022 after selling out during the quarter.
- SG Americas Securities sold 3,444 Freeline Therapeutics Holdings shares in Q3 2022, an estimated $45K.
- SG Americas Securities first reported a position in Freeline Therapeutics Holdings in Q3 2021 and held it in 4 quarters.
- SG Americas Securities's Freeline Therapeutics Holdings position peaked at $163K in Q3 2021.
- 14 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings as of Q3 2022.
Based on SG Americas Securities's 13F filing for Q3 2022, filed 31 Oct 2022.